NCT03504956 Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
| NCT ID | NCT03504956 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Coronary Atherosclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2018-07-30 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2018-07-30 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.
Eligibility Criteria
Inclusion: * Healthy Volunteers: male or female ≥ 18 years of age with a BMI\<30, with no history of cardiovascular disease * Patients: Medically stable, male or female ≥ 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery Exclusion: * Contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy. * Inability to tolerate MR imaging secondary to an inability to hold breath for a short time or have claustrophobia. * Non-compliant with visit instructions, including following procedure instructions * Severe allergy to animal dander or animal-instigated asthma * Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR \<45ml/min) or previous allergic reaction to gadolinium-based contrast agents.\* * Volunteers who have had four or more prior previous gadolinium contrast scan
Contact & Investigator
Debiao Li, PhD
PRINCIPAL INVESTIGATOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT03504956 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03504956 currently recruiting?
Yes, NCT03504956 is actively recruiting participants. Contact the research team at Rosalia.DeLeon@cshs.org for enrollment information.
Where is the NCT03504956 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT03504956 clinical trial?
NCT03504956 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Debiao Li, PhD at Cedars-Sinai Medical Center. The trial plans to enroll 150 participants.